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Background: DNA electroporation has been demonstrated in preclinical models to be a promising strategy to
improve cancer immunity, especially when combined with other genetic vaccines in heterologous prime-boost
protocols. We report the results of 2 multicenter phase 1 trials involving adult cancer patients (n=33) with stage II-IV
disease.
Methods: Patients were vaccinated with V930 alone, a DNA vaccine containing equal amounts of plasmids
expressing the extracellular and trans-membrane domains of human HER2, and a plasmid expressing CEA fused to
the B subunit of Escherichia coli heat labile toxin (Study 1), or a heterologous prime-boost vaccination approach
with V930 followed by V932, a dicistronic adenovirus subtype-6 viral vector vaccine coding for the same antigens
(Study 2).
Results: The use of the V930 vaccination with electroporation alone or in combination with V932 was well-
tolerated without any serious adverse events. In both studies, the most common vaccine-related side effects were
injection site reactions and arthralgias. No measurable cell-mediated immune response (CMI) to CEA or HER2 was
detected in patients by ELISPOT; however, a significant increase of both cell-mediated immunity and antibody titer
against the bacterial heat labile toxin were observed upon vaccination.
Conclusion: V930 vaccination alone or in combination with V932 was well tolerated without any vaccine-related
serious adverse effects, and was able to induce measurable immune responses against bacterial antigen. However,
the prime-boost strategy did not appear to augment any detectable CMI responses against either CEA or HER2.
Trial registration: Study 1 – ClinicalTrials.gov, NCT00250419; Study 2 – ClinicalTrials.gov, NCT00647114.
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Interest in cancer immunotherapy has been revived with
the 2010 US Food and Drug Administration approval of
sipuleucel-T, the first approved therapeutic vaccine for the
treatment of advanced cancer [1,2]. The recent approval of
the CTLA-4 monoclonal antibody ipilimumab has gener-
ated further interest in immune-based therapies in cancer
[3,4]. However, while cancer vaccinations are well-tolerated,
the vast majority of peptide/protein and cell-based vaccines
have failed to induce sufficient immune responses to pro-
vide long-lasting clinical benefits [5]. DNA plasmid-based
vaccines have significant advantages over cell-based or pep-
tide platforms—they are highly amenable to modifications
(e.g., multiple epitopes, codon optimization, inclusion of
danger signals, and/or cytokines) that could result in en-
hanced immunogenicity and superior clinical activity [6,7].
Although the use of DNA vaccines has shown great
promise in preclinical models, results of early phase clin-
ical trials have been rather disappointing [8]. Challenges
for DNA vaccines include the fact that the amount of
plasmid DNA that can be injected in humans is substan-
tially lower than in preclinical studies, and the poor level
of cellular DNA uptake. However, DNA injection into
skeletal muscle followed by a short electrical stimulation,
also referred to as electro-gene-transfer or electropor-
ation (EP), significantly enhances DNA uptake and gene
expression [9,10]. In the case of self-antigens (e.g., tumor-
associated antigens), this approach has been shown, in
some preclinical studies, to result in the induction of
strongly protective immune responses [11]. Although the
mechanism remains unknown, it is speculated that transi-
ent pores on the cell surface could lead to enhanced anti-
gen expression and transient tissue damage may lead to
the recruitment of inflammatory cells and production of
cytokines [12].
Replication-defective E1-deleted recombinant adenovi-
ruses (Ad) have proven to be very efficacious in inducing
strong antibody and cellular antigen-specific immune re-
sponses against a variety of antigens in several species,
[13-17] and have been tested in human clinical trials
with antigens from HIV-1 [18,19]. Adenoviral vectors
are also being evaluated in clinical trials using DNA vac-
cine priming regimens followed by Ad vector–boosted
immunizations (heterologous prime-boost immunization
regimens) [20]. Results indicate that these regimens are
capable of generating higher amplitude and more dur-
able immune responses, leading to potentially better
prophylactic and therapeutic efficacy in a variety of pre-
clinical disease models [21-23]. The combined treatment
of Ad vectors with DNA electroporation (DNA-EP) may
give rise to superior immune responses that could result
in clinical benefit in cancer patients [6,24].
Because many solid tumors overexpress human epider-
mal growth factor receptor 2 (HER2) and carcinoembryonicantigen (CEA), they are good targets for immunotherapy
[25,26]. Both HER2 and CEA are cell surface markers in-
volved in cell-mediated immunity (CMI) and antibody-
dependent cell-mediated cytotoxicity (ADCC) [25,27]. In a
series of preclinical studies, we have shown that when
inserted into Ad vectors or delivered via DNA-EP, codon-
optimized versions of the CEA and HER2 complementary
DNAs (cDNAs) are capable of inducing potent T- and B-
cell immune responses and break tolerance to self in mice
and nonhuman primates [13,28,29]. Immune responses are
further enhanced when CEA is fused to the B subunit of
Escherichia coli heat labile enterotoxin (LTB),[13,30] and
when HER2 is truncated to exclude the intracellular do-
main [31]. Furthermore, the heterologous DNA-EP prime-
Ad boost vaccination regimens have potent antitumor
efficacy in colon and breast cancer mouse models when an-
imals were vaccinated against CEA or HER2, respectively
[13,32]. Based on these results, we generated a dual-
component human vaccine V930 DNA-EP/ V932 Ad. V930
is a bivalent DNA plasmid vaccine consisting of 2 separate
plasmids—one expressing the extracellular (ECD) and
transmembrane (TM) domains of human HER2, and the
other expressing human CEA fused to the LTB. V932 is a
dicistronic adenoviral vaccine vector, which encodes both
human CEA fused to LTB and the truncated version of hu-
man HER2 tumor antigen (HER2-ECDTM). CEA was
fused to LTB with the intent to enhance immune response
to CEA by enhancement of cross-priming. Expression of
CEA-LTB is driven by the human cytomegalovirus immedi-
ate early (CMV IE) promoter, whereas the mouse CMV IE
promoter drives expression of HER2-ECDTM. Since pre-
clinical and clinical data have shown that DNA vaccines ap-
pear to be effective at priming when followed by viral
vector boosting, the combined treatment with DNA-EP
and adenoviral vaccine may give rise to superior immune
responses that may result in increased efficacy. We
conducted 2 separate phase 1 trials in cancer patients
whose tumors expressed CEA and/or HER2 in order to
evaluate the safety/tolerability, as well as the immunogen-
icity, of the bivalent DNA plasmid vaccine V930 with EP
injection alone (Study 1) or as a heterologous prime-boost




Two multicenter, phase 1, open-label dose escalation trials
were conducted in adult cancer patients with histologically
confirmed stage II-IV solid malignancies expressing HER2
and/or CEA. The phase I trials were designed with only a
low dose and a high dose cohort, with escalation to the high
dose being done after 6 patients completed vaccinations
without any severe adverse toxicities. The primary end point
of Study 1 (ClinicalTrials.gov identifier: NCT00250419;
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002) was to determine the safety and immunogenicity of
escalating doses of V930 administered as an intramuscular
(IM) vaccination followed by EP. The primary end point
of Study 2 (ClinicalTrials.gov identifier: NCT00647114;
http://clinicaltrials.gov/ct2/show/NCT00647114; Protocol
003) was to assess the safety/tolerability and immunogen-
icity of the heterologous vaccine prime-boost approach
consisting of V930 DNA-EP at a fixed dose followed 4 and
6 weeks later by vaccination with V932 Ad, a dicistronic
adenovirus subtype 6 viral vector vaccine coding for both
CEA and HER2 (Figure 1). In both studies, gene delivery
into cells was aided by EP with the MedPulser™ DDS im-
mediately following intramuscular injection of V930 DNA.
Study participants
Both studies were conducted in accordance with princi-
ples of the Declaration of Helsinki, in compliance with
Good Clinical Practice (GCP), and approved by the ap-
propriate institutional review boards and regulatory
agencies. A written informed consent was obtained fromFigure 1 V930 DNA plasmids (a) and V932 adenoviral vector (b) enco
consisting of a plasmid expressing the ECD and TM domains of HER2 and
encodes human CEA fused to LTB and the truncated version of human HE
the human CMV IE promoter, whereas mouse CMV IE promoter drives thepatients prior to participating in the studies, in accordance
with GCP. Men or women with stage II-IV solid malignan-
cies shown to express HER2 and/or CEA by immunohisto-
chemistry, at least 18 years old at the time of clinical trial
entry were enrolled. Patients were required to have com-
pleted standard adjuvant therapy (radiotherapy, chemo-
therapy, or biologic therapy) at least 1 month prior to
enrollment or refused standard adjuvant therapy when ren-
dered disease-free following surgery. Additionally, for lo-
cally advanced or metastatic cancers, the patient’s disease
status, assessed within 2 weeks prior to enrollment, had to
have been stable (≥3 months). Additionally, patients were
required to have a Karnofsky performance status of 80 to
100 at the time of study entry. Women of childbearing po-
tential had to demonstrate a non-gravid state prior to and
had to agree to contraceptive use or abstinence during the
study period.
Primary exclusion criteria included known history of
HIV or hepatitis B or C; active medical conditions (e.g.,
arrhythmia or myocardial infarction) within the last 3 -
months; presence of an implantable cardiofibrillatording for HER2/neu and CEA. V930 is a bivalent DNA plasmid vaccine
a plasmid expressing CEA fused to the B subunit of E coli LTB. V932 Ad
R2 tumor antigen (HER2-ECDTM). The CEA-LTB expression is driven by
expression of HER2-ECDTM.
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disorder; history of splenectomy or autoimmune disor-
ders; receiving immunosuppressive therapy; known his-
tory of coagulopathy or thrombocytopenia prohibiting
IM injections; symptomatic ascites or pleural effusion;
recent receipt of a non-study vaccine or any investiga-
tional drug; or allergy to any of the vaccine components.
Patients with a history of a second malignancy were also
excluded, with some exceptions.
Vaccination schedule
Patients enrolled in Study 1 were vaccinated with V930
DNA-EP at one of 2 different sequential dose levels:
0.25 mg DNA/injection (low dose) or 2.5 mg DNA/in-
jection (high dose). At each dose level, patients received
a series of 5 IM injections of V930 DNA-EP adminis-
tered every 14 days (on days 1, 15, 29, 43, and 57) as a
0.5-mL injection given at a 90° angle into the deltoid
muscle of alternating arms using a 1.0-mL syringe with a
27-gauge, 1.27-cm needle (Figure 2). Within 2 minutes
of the injection, each patient was given an EP IM injec-
tion consisting of two 60-millisecond pulses using the
MedPulser™ DDS device.
In Study 2, patients also received a series of 5 V930
DNA-EP vaccinations (2.5 mg/injection, the highest dose
evaluated in Study 1) administered the same way as in
Study 1. This was followed by a prime-boost approach,
with 2 series of V932 Ad injections given 4 and 6 weeks
after the fifth vaccination with V930 DNA-EP (Figure 2).
Patients went on to receive one of 2 possible dose levels
of V932 Ad: 0.5 × 109 vg/injection (low dose) or 0.5 ×
1011 vg/injection (high dose). Provided they continued to
meet eligibility criteria, patients from Study 1 who had
completed the high-dose regimen of V930 DNA-EP
(2.5 mg/injection) were eligible to enroll directly intoFigure 2 Vaccination schedule with V930 DNA-EP alone (Study 1) and
tolerated the highest dose of V930 DNA-EP (2.5 mg/injection) in Study 1 w
completed all 5 V930 vaccinations at least 4 weeks and no more than 24 wStudy 2, as long as at least 4 weeks but no more than
24 weeks had elapsed since the fifth and final injection
of V930 DNA-EP. Patients were followed for 1 year after
the last vaccination for safety and immunogenicity.
Patients only received the respective high-dose level of
either V930 DNA-EP (Study 1) or V932 Ad (Study 2) after
6 patients had completed the entire low-dose vaccination
regimen of each study and a 4-week post-observation
period. No intra-patient escalation was allowed in either
study.
Study procedures
In both studies, patients were observed for approxi-
mately 30 minutes immediately after each treatment for
adverse reactions. Patients were asked to complete a
treatment report card to record oral evening tempera-
tures, and any injection-site reactions for 5 days follow-
ing each treatment, as well as to record systemic adverse
events (AEs) throughout the study. Adverse experiences
were graded and recorded according to National Cancer In-
stitute Common Toxicity Criteria for Adverse Events (NCI-
CTCAE v3.0). In both studies, a dose-limiting toxicity
(DLT) was defined as vaccine- or EP-related AEs including
any of the following: grade 4 neutropenia; grade 3 neutro-
penia with fever (>38.5°C); grade 4 thrombocytopenia (≤25
× 109/L); any grade 3 or 4 non-hematologic toxicity (except
alopecia and inadequately treated diarrhea, nausea and
vomiting); and grade 3 transaminitis (lasting ≥1 week).
Grade 3 or 4 creatine phosphokinase (CPK) elevations were
not considered DLTs unless they were associated with evi-
dence of rhabdomyolysis (as assessed by renal or other
organ dysfunction). Any patient experiencing a DLT was
not to receive any additional vaccines, and would have
automatically entered into the follow-up phase of the study.
Hematology and serum chemistry laboratory safety testscombined V930 DNA-EP→ V932Ad (Study 2). Patients who safely
ere allowed to enroll directly into Study 2, provided they had
eeks prior to entry and met all other eligibility criteria.
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mune dysfunction (e.g., ANA, anti-dsDNA, C3) were to be
measured only if there was evidence of an autoimmune ad-
verse experience (e.g., rash and constitutional symptoms).
For Study 1 only, patients were asked to assess the sever-
ity of the pain experienced at 1, 5, 10, and 20 minutes, and
24 hours after each V930 DNA-EP injection using 2 vali-
dated instruments: the McGill Pain Questionnaire and the
Brief Pain Inventory (BPI), which included a single ques-
tion (“Please rate your pain by circling the number that
tells how much pain you have right now,” rated on a scale
from 0 [no pain] to 10 [pain as bad as you can imagine]).
Pain associated with the vaccination/EP procedure was
assessed on the same days as vaccinations, and reported as
an AE if it was considered grade 3 or 4, was a serious ad-
verse event (SAE), or resulted in study discontinuation.
Study-related visits were divided into a vaccination
period of 2 months and a follow-up period for safety and
immunogenicity starting at the end of vaccinations and
lasting up to 1 year. Visits 1 to 7 were done during the vac-
cination period, and visits 8 to13 during follow-up. During
the vaccination period, physical exam and chemistry labs
were performed at baseline and on days 1, 29, and 57.
Evaluation of Karnofsky performance status, hematology
labs, AEs, and injection sites was performed at baseline
and on days 1, 15, 29, 43 and 57. Peripheral blood mono-
nuclear cell, ELISA sample, and tumor marker collection
were done at baseline and on days 1 and 43. Patients were
assessed for toxicity of both the vaccine and the EP tech-
nique at each visit and at subsequent follow-up visits. Im-
munologic assessments for CMI were assessed at baseline
and periodically during the study and follow-up.
Laboratory assays
HER2- and CEA-specific CMI, measured by the interferon-
gamma (IFN-γ) enzyme-linked immunospot (ELISPOT)
assay, were determined at baseline and various times during
and post vaccination, as well as ELISA for antibody re-
sponses as previously published [33]. The IFN-γ ELISPOT
assay was the primary immunogenicity outcome measured
and used pools of 15-mer peptides covering the entire cod-
ing sequence of the immunizing tumor antigens. In both
studies, based on available data, positive immune responses
were defined as both: (i) at least 35 spot forming cells per
million peripheral blood mononuclear cells (35 SFC/106
PBMCs), and (ii) a 3.5-fold or greater increase above back-
ground levels; this 2-dimensional criterion represents a low
false positive rate of 1% or less. Staphylococcus aureus
enterotoxin B (SEB) was used as a positive control in
ELISPOTassays.
Statistical considerations
In both studies, safety and tolerability were assessed by
tabulating AEs and summarizing duration, intensity, andtime to onset of toxicity by dose level. The incidence of
vaccination-related AEs and EP-related AEs was also
summarized by dose. For Study 1, summary statistics
(mean, median, minimum, maximum, and standard de-
viation) were generated for the McGill Pain Question-
naire and BPI instrument scores at each time point
measured after EP injection. HER2- and CEA-specific
CMI as measured by ELISPOT were summarized at
baseline and at various times during and post vaccin-
ation. If 2 or fewer CMI responses to either HER2 or
CEA were observed within the 20-patient cohort receiv-
ing the 2.5-mg plasmid dose, the 90% confidence inter-
val (CI) of the true response rate would lie completely
below 30%. Likewise, the 90% CI for the true response
rate would lie completely above 30% if the observed re-
sponse rate for both antigens is at least 50%.
In Study 2, a Simon 2-stage optimal design was used
based on CMI response [34]. In the first stage, 12
evaluable patients were to be enrolled into the high-dose
V932 Ad group. If 2 or more patients had a detectable
CMI response in the first stage, then 23 additional pa-
tients would be enrolled. If 6 or more of the 35 total pa-
tients enrolled were found to have a CMI response, then
the design would consider the drug to warrant more ex-
tensive development. This ensured an approximate 90%
chance of continuing development of the drug if the true
CMI response rate was 30% and a 10% chance of con-




A total of 33 subjects were enrolled into 2 studies from
3 centers in the United States between July 2007 and
May 2009. Study 1 evaluated the safety of the V930
DNA vaccine alone. Twenty-eight patients—6 at the low
dose and 22 at the high dose—were enrolled in the V930
DNA-EP alone trial (Study 1): 27 (96%) received all 5 IM
V930 vaccinations followed by EP and one prematurely
discontinued due to the detection of liver metastases
after the fourth vaccination. Study 2 was a second phase
1 trial that evaluated the V930 DNA-EP prime-Ad boost
strategy (V930 DNA-EP→V932 Ad boost study). Eleven
patients were enrolled into the V930 DNA-EP→V932
Ad boost study, of which 6 eligible patients who had
previously participated in Study 1. Therefore, only 5 new
patients that had not previously participated in Study 1
were enrolled into Study 2. All 11 patients (5 new pa-
tients and 6 from Study 1) had received at least one in-
jection of V930 DNA-EP: 8 (73%) received all 5
injections of V930 and at least one injection of V932 Ad;
7 (64%) received both V932 Ad injections; 6 received the
low V932 Ad dose; and 5 (45%) received the high V932
Ad dose. One patient (AN333) who only received a
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progression. Six patients (55%) completed Study 2, with 5
patients (46%) discontinuing prior to trial completion
(4 due to progressive disease, while one withdrew consent).
Overall, the average patient age was approximately 60 -
years, and most patients were women (59%). The most
common cancer diagnoses in both studies overall were
colorectal cancer (36%), breast cancer (25%), and non-
small cell lung cancer (21%) (Table 1). Most patients who
were enrolled in both studies had advanced disease. Most
patients had received prior chemotherapy with 30 (97%)
having received at least one prior line of chemotherapy.Table 1 Patient demographics and baseline characteristics
Baseline characteristic Study 1
V930 DNA-EP V930 DN
0.25 mg 2.5 mg
(n=6) (n=22)
Age, years (mean ± SD) 66.8 ± 9.2 58.6 ± 15
Gender, n (%)
Male 2 (33) 8 (36)
Female 4 (67) 14 (64)
Race, n (%)
White 6 (100) 21 (96)
Other 0 1 (4.5)
KPS, n (%)
100 6 (100) 17 (77)
90 0 5 (23)
Tumor diagnosis, n (%)
Adenocarcinoma NOS 1 (17) 1 (5)
Breast cancer 0 7 (32)
Colorectal cancer 4 (67) 6 (27)
Non-small cell lung cancer 1 (17) 5 (23)
Ovarian cancer 0 1 (5)
Pancreatic cancer 0 1 (5)
Squamous cell carcinoma 0 1 (5)
NOS 0 0
Renal cancer 0 0
Bladder cancer 0 0
Prior lines of chemotherapy, n (%)
0 0 0
1 6 (100) 11 (50)
2 0 5 (23)
≥3 0 6 (27)
Stage IV cancer 0 (0) 11 (50)
aSix eligible patients from Study 1 were enrolled into Study 2. Therefore, only 5 pat
2. Overall 33 patients (not 39) were enrolled in both studies.
KPS: Karnofsky performance status; NOS, not otherwise specified; SD, standard deviaVaccine safety
The V930 DNA-EP vaccine, in the initial Phase 1 trial
where DNA vaccine alone was given (Study 1), was well-
tolerated, at both 0.25 mg and 2.5 mg per vaccination,
with no observed DLTs. In Study 1, 71% of patients ex-
perienced a clinical (non–injection site) grade 1 or 2 AE,
with fatigue (21%) being the most common. Other AEs
(reported by >10% of patients) included diarrhea (25%),
nausea (14%), arthralgias (14%), abdominal pain (11%),
and insomnia (11%) (Table 2). The only SAE was grade
3 abdominal pain, observed in 2 patients (9%) in the 2.5-
mg treatment group and considered by the investigatorStudy 2a
A-EP V932 Ad V932 Ad
0.5 × 109 vg/injection 0.5 × 1011 vg/injection
(n=6) (n=5)
.9 58.8 ± 12.9 54.4 ± 8.6
2 (33) 4 (80)
4 (67) 1 (20)
5 (83) 5 (100)
1 (16.7) 0




1 (17) 1 (20)








2 (33) 1 (20)
3 (50) 1 (20)
1 (17) 2 (40)
4 (67) 3 (60)
ients that had not previously participated in Study 1 were enrolled into Study
tion.
Table 2 Grade 1 or 2 adverse events occurring in at least 2 patients
Adverse event, n (%) Study 1 Study 2a
V930 DNA-EPb V930 DNA-EPb V932 Adc V932 Adc
0.25 mg 2.5 mg 0.5 × 109 0.5 × 1011
vg/injection vg/injection
(n=6) (n=22) (n=6) (n=5)
Diarrhea 2 (33) 5 (23) 0 0
Fatigue 1 (17) 5 (23) 1 (17) 1 (20)
Arthralgias 1 (17) 3 (14) 2 (33) 0
Nausea 0 4 (18) 0 0
Skin & subcutaneous tissue disorders 1 (17) 3 (14) 1 (17) 1 (20)
Abdominal pain 0 3a (14) 0 0
Infections 0 3 (14) 1 (17) 0
Insomnia 1 (17) 2 (9) 0 0
Constipation 0 2 (9) 0 0
Dizziness 0 2 (9) 1 (17) 0
Dyspnea 0 4 (18) 1 (17) 0
Hot flushes 0 2 (9) 0 0
Musculoskeletal pain 0 2 (9) 4 (67) 4b (80)
Vomiting 0 2 (9) 0 0
Creatinine elevation (grade 1) 0 1 (5) 0 2 (40)
aSix eligible patients from Study 1 were enrolled into Study 2. Therefore, only 5 patients that had not previously participated in Study 1 were enrolled into Study
2. Overall 33 patients (not 39) were enrolled in both studies.
bAll adverse events with DNA vaccine alone (V930 DNA-EP) were Grade 1-2, with the exception of one case of grade 3 abdominal pain felt to be unrelated to
study drug in the treatment phase and one case of grade 3 abdominal pain due to small bowel obstruction in the follow-up phase believed to be related to the
tumor and not related to study drug.
cAll averse events with V930 DNA-EP→V932Ad were grades 1 or 2, with the exception of one patient who experienced grade 3 muscle spasm in the low-dose
V932 Ad group and one patient with ankle pain and unilateral leg pain in the high-dose V932Ad group. Both were not related to the study drug, as determined
by the investigator.
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the treatment period or during the 1-year follow-up.
Grade 1 or 2 AEs identified as an injection site reaction
were reported in 71% of patients. The incidence of injec-
tion site AEs appeared comparable between the 0.25 mg
(83%) and 2.5 mg (68%) treatment groups; none of the
reported injection site AEs were worse than grade 2.
The most commonly observed V930 injection site AEsTable 3 Grade 1 or 2 injection site reactions (incidence ≥1% i
Adverse event, n (%) Study 1
V930 DNA-EP V930 DNA-EP
0.25 mg 2.5 mg
(n=6) (n=22)
Injection site erythema 1 (17) 14 (64)
Injection site pain 4 (67) 9 (41)
Injection site swelling 1 (17) 8 (36)
Injection site bruising 1 (17) 1(5)
Injection site papule 0 1(5)
Injection site rash 0 1(5)
aSix eligible patients from Study 1 were enrolled into Study 2. Therefore, only 5 pat
2. Overall 33 patients (not 39) were enrolled in both studies.included erythema (54%), site pain (46%), and swelling
(32%) (Table 3).
The V932 Ad vaccine was also well-tolerated without
any vaccine-related SAEs. During the combined heterol-
ogous V930 DNA-EP→V932Ad boost treatment and
follow-up phase in Study 2, most patients (82%) experi-
enced grade 1 or 2 AEs: the most common were fatigue
(18%) and elevated creatinine (18%) (Table 2). Six patientsn one or more treatment groups)
Study 2a
V932 Ad V932 Ad
0.5 × 109 vg/injection 0.5 × 1011 vg/injection
(n=6) (n=5)
0 3 (60)
1 (17) 4 (80)




ients that had not previously participated in Study 1 were enrolled into Study
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drug–related. Injection site AEs with V932 Ad appeared to
be dose-related, as they were reported in a higher fre-
quency in the higher 0.5 × 1011 vg/injection dose level
(80%) than the lower 0.5 × 109 vg/injection dose level
(33%). The most commonly observed V932 Ad injection
site AEs included pain (45%), erythema (27%), and swelling
(27%) (Table 3). None of the reported injection site reac-
tions were greater than grade 1. Two of 11 patients (18%)
experienced grade 3 SAEs (muscle spasm and unilateral leg
pain) considered not related to the vaccine. None of the 11
patients administered V932 Ad experienced a SAE during
the treatment phase. No patient deaths were reported dur-
ing the treatment phase or the 1-year follow-up period.
Pain experienced from electroporation
It was initially anticipated that V930 DNA-EP vaccination
would be tolerable, and that patients would not experience
severe pain from this technique. To determine whether
this indeed was the case, self-reported pain scores were
collected from patients who had received V930 DNA-EP
alone (Study 1). The median worst pain score reported
with the McGill Pain Questionnaire, averaged over the
study, was 2 (discomfort), reported by 8 of 28 patients
(29%); only 4 patients (14%) rated their worst pain as ei-
ther 4 (horrible) or 5 (excruciating) (Table 4). Over the en-
tire study, 18 patients (64%) reported their worst pain as 2
or less on the 10-point Brief Pain Inventory scale, with
only 2 (7%) rating their worst pain as 6 or greater.
Immunogenicity
Longitudinal antigen-specific T-cell responses to CEA,
HER2, and LTB from baseline levels to approximately 4
weeks after completion of the fourth V930 vaccination
(i.e., ~87 days after the first vaccination) showed that
none of the 28 patients vaccinated with V930 achieved a
CMI response to CEA or HER2, based on ex-vivo IFN-γ
ELISPOT assays (Figure 3). None of the 11 patients vac-
cinated according to the heterologous V930 DNA-
EP→V932 Ad approach demonstrated a measurable
CMI response to CEA or HER2 (data not shown).
Subsequently, analyses designed to look for evidence of a
threshold-independent CMI response were performed.
These exploratory analyses were limited to 24 patients for
whom ELISPOT data were available from baseline through
visit 8 (2 weeks after the last of the 5 immunizations). Six
of the 24 patients were in the low-dose group; the
remaining 18 were in the high-dose group. Similar to the
pre-specified analyses, no evidence of an increase in CEA-
or HER2-specific cell mediated lymphocyte responses was
observed following vaccination (P>0.05, paired t-test or
signed-rank test) when comparing ELISPOT responses at
visit 8 versus baseline (mean ELISPOT responses at visit 1
and 2).By contrast, the LTB component of V930 DNA-EP
elicited significant increases in CMI responses at day 72
post vaccination versus baseline (P<0.001, paired t-test
or signed-rank test) (Figure 4). Based on the positive
LTB ELISPOT data, antibody responses against LTB at
visit 2 and 8 were determined and compared. Immu-
nized patients had significantly higher anti-LTB antibody
titers at visit 8 versus visit 2 based on anti-LTB ELISA
(P<0.001, paired t-test or signed-rank test) (data not
shown). Because of evidence of pre-existing LTB-specific
T-cell and antibody responses at baseline, the immuno-
genicity of the LTB component of V930 could, in part,
be due to recall responses to this microbial antigen. Not-
ably, there was a trend toward a higher boosting effect in
the high-dose group compared with the low-dose group.
Due to the relatively short length of the needle used for
injection of the DNA and electrodes used with the EP
device, there was concern that in patients with higher
body mass index (BMI), a true IM injection may not be
achieved; therefore, BMI may have led to greater variabil-
ity in immune responses. In order to determine whether
BMI may have affected vaccination, we analyzed the rela-
tionship between weight and BMI and anti-LTB antibody
titers. No significant correlation between anti-LTB anti-
body responses and patient weight or BMI was observed
(Figure 5), suggesting that patients with higher BMIs were
adequately vaccinated.
Discussion
In this report, we describe the results of 2 phase 1 trials
aimed at evaluating the safety/tolerability and immuno-
genicity of the bivalent DNA plasmid vaccine V930 with
EP injection alone or in a heterologous approach
consisting of V930 DNA-EP followed by V932 Ad boost.
Similar to other previously published DNA vaccine tri-
als,[35] our immunization regimens appeared to be safe
and well-tolerated. With regards to immunogenicity,
only responses to the bacterial portion of the vector
were detected—none of the vaccinated subjects had de-
tectable cell-mediated responses by ex-vivo ELISPOT to
either CEA or HER2. Detectable immune responses
against the LTB component of the vaccine imply that
the vector was successfully delivered for antigen presen-
tation. On the other hand, undetectable immune re-
sponses against the tumor antigens included in the
vaccine supports tumor-associated antigens as poor im-
munogens. Even the heterologous approach, which has
been reported before as enhancing immune responses,
did not seem to improve the overall immunogenicity of
either CEA or HER2 cancer antigens.
Weak immunogenicity of tumor antigens is perhaps
the biggest challenge for cancer vaccine development,
but also represents a significant opportunity for genetic
vaccines [36]. DNA vaccine vectors can be readily
Table 4 Worst pain experienced after electroporation (Study 1) as measured by the McGill Pain Questionnaire (0-5)a
V930 DNA-EP V930 DNA-EP Total
0.25 mg 2.5 mg
n (%) n (%) n (%)
Total number of patients 6 22 28
Worst pain experienced by patient:
entire studyb 1 (17) 3 (14) 4 (14)
0 2 (33) 4 (18) 6 (21)
1 2 (33) 6 (27 8 (29)
2 1 (17) 5 (23) 6 (21)
3 0 2 (9) 2 (7)
4 0 2 (9) 2 (7)
5
Worst pain experienced by patient: day 1b
0 1 (17) 6 (27) 7 (25)
1 3 (50) 5 (23) 8 (29)
2 2 (33) 5 (23) 7 (25)
3 0 4 (18) 4 (14)
4 0 1 (5) 1 (4)
5 0 1 (5) 1 (4)
Worst pain experienced by patient: day 15b
0 3 (50) 4 (18) 7 (25)
1 3 (50) 6 (27) 9 (32)
2 0 6 (27) 6 (21)
3 0 3 (14) 3 (11)
4 0 2 (9) 2 (7)
5 0 1 (5) 1 (4)
Worst pain experienced by patient: day 29b
0 3 (50) 5 (23) 8 (29)
1 1 (17) 5 (23) 6 (21)
2 1 (17) 7 (32) 8 (29)
3 1 (17) 2 (9) 3 (11)
4 0 1 (5) 1 (4)
5 0 2 (9) 2 (7)
Worst pain experienced by patient: day 43b
0 2 (33) 4 (18) 6 (21)
1 2 (33) 8 (36) 10 (36)
2 2 (33) 5 (23) 7 (25)
3 0 2 (9) 2 (7)
4 0 1 (5) 1 (4)
5 0 2 (9) 2 (7)
Worst pain experienced by patient: day 57b
0 2 (33) 5 (23) 7 (25)
1 2 (33) 8 (36) 10 (36)
2 1 (17) 2 (9) 3 (11)
3 1 (17) 3 (14) 4 (14)
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Table 4 Worst pain experienced after electroporation (Study 1) as measured by the McGill Pain Questionnaire (0-5)a
(Continued)
4 0 1 (5) 1 (4)
5 0 2 (9) 2 (7)
aThe McGill Pain Questionnaire measured pain on a 6-point scale: 0 = no pain, 1 = mild, 2 = discomforting, 3 = distressing, 4 = horrible, and 5 = excruciating.
bAs ranked by the patient.
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tailored to facilitate uptake and presentation, and immu-
nomodulatory components (e.g., danger signals or acti-
vating cytokines) can be incorporated. All these factors
combined should enhance protective antitumor re-
sponses. However, encouraging results from preclinical
testing of new and improved vaccine vectors are damp-
ened by the overwhelming difficulty associated with clin-
ical testing. Our ability to detect immune responses
against the bacterial portion of the vaccine vector fur-
ther validates EP as a viable option for vaccine delivery,
especially those targeting pathogens. Given the intrinsic
differences between immune responses against self and
foreign antigens, perhaps longer availability of vaccine
components (i.e., antigen and adjuvant) at the site of in-
jection would increase the opportunity for professional
antigen-presenting cells to uptake the antigen under op-
timal stimulatory conditions that would overcome in
some extent the lack of robust immunogenicity.
A general established limitation of DNA vaccines is
the injection dose of DNA. It is now understood that the
clinical success of DNA vaccines in mice was greatly due
to local damage caused by the hydrostatic pressure of aFigure 3 Frequencies of CEA and HER2/neu specific IFN-γ
producing T cells following high-dose V930 DNA-EP
vaccination. Longitudinal frequencies were determined from
evaluable subjects (n=14); the threshold for CMI response was ≥35
SFC/106 PBMC and ≥3.5-fold above mock (i.e., control well levels
[red line]). Differences between time points or between CEA and
HER2 and mock were not significant (P>0.05 by Wilcoxon rank sum
test). Arrow shows day of last V930-DNA-EP vaccination.volume of 50 μl. Unfortunately, scaling up to an equiva-
lent volume and dose of DNA in human subjects is not
feasible with current technology; therefore, alternative
methods are required. Recent data generated also point
to the potential interference of 2 vectors/expression cas-
settes as another limitation (personal communication, G.
Ciliberto & L. Aurisicchio). V930 is a mixture of 2 plas-
mids with the same regulatory elements (human CMV
IE). Similarly, V932 Ad is a dicistronic vector where hu-
man CMV IE and mouse CMV IE drive the expression
of CEA-LTB and HER2, respectively. Competition firstFigure 4 Longitudinal cell-mediated and antibody responses to
LTB. a) Frequencies of LTB-specific IFN-γ producing T cells from
evaluable subjects in both Studies 1 and 2, who had received low-
or high-dose V930 DNA-EP vaccination. Arrow shows day of last
V930-DNA-EP vaccination. Differences in peak values (day 87) from
baseline levels were statistically significant for anti-LTB antibody
responses (*P=0.03 by Wilcoxon rank sum test). b) Anti-LTB antibody
responses. Differences in peak values (day 87) from baseline levels
were statistically significant for the high-dose cohort (P<0.007 by
Wilcoxon rank sum test). Peak levels (day 72) for the low-dose
cohort were not significantly different from baseline levels (P>0.05).
Figure 5 Correlation between anti-LTB antibody response, and BMI or weight. A bivariate analysis was performed to determine if BMI or
weight were inversely correlated with an LTB response. No effect of weight or BMI was seen on the ratio of post-vaccination to pre-vaccination
anti-LTB titers (P>0.20 in each case). LTB, Escherichia coli heat labile enterotoxin, B subunit; BMI, body mass index.
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factors within the nucleus, may affect antigen expression
levels and their immunogenicity. This may be particularly
relevant for the immune response against self-antigens.
A major limitation of these 2 Phase 1 trials was that
they included a rather heterogeneous population of pa-
tients (i.e., different clinical stages and cancer diagnoses).
While CEA and HER2/neu are expressed in a wide var-
iety of solid tumors, having such heterogeneity likely
prevented any meaningful conclusions. Moreover, one
potential explanation for the poor immunogenicity ob-
served with the heterologous prime boost strategy with
CEA and HER2 tumor antigens may be due to a large
proportion of enrolled patients with metastatic disease.
Because of the myriad strategies tumors employ to evade
the immune system (e.g., myeloid derived suppressor
cells and regulatory T-cells), a vaccine that elicits a po-
tential immune response in the adjuvant setting may be
erroneously discounted if tested in the metastatic setting
as not being immunogenic enough to generate clinical
activity [37,38]. The optimal setting to test vaccines in
cancer patients would likely be in patients who have
completed definitive curative first-line therapy, and have
a high risk of recurrent disease. To our knowledge,
sipuleucel-T is the only cancer vaccine strategy that has
been shown in late-phase trials to have modest clinical
efficacy in patients with widespread metastatic disease[1,39,40]. Interestingly, a measurable immune response
against the cancer antigen prostatic acid phosphatase was
detectable only in less than 30% of sipuleucel-T vaccinated
patients [41]. Therefore, the sensitivity of conventional im-
munological assays may probably be inadequate for de-
tection of immune responses against cancer antigens.
However, a large number of other vaccine-based strategies
have not been successful in the metastatic setting [42]. It is
also important to note that, while the immune system in a
metastatic host may block development of robust immune
response to cancer vaccines, this is not universally true,
and in the literature there are reports of a wide array of
cancer vaccines associated with detectable immune re-
sponses in several early phase studies in patients with dif-
ferent metastatic solid tumors [43-48].
Conclusions
Based on prior studies and results from our studies, one
could conclude that the heterologous prime boost ap-
proach was well tolerated but ineffective with regards to
generating immune responses against cancer antigens.
However, due to the very small number of patients (n=5)
that received the high dose of V930 DNA-EP followed
by high-dose V932 Ad vaccinations, no statistically sig-
nificant conclusions can be drawn regarding the heterol-
ogous prime boost approach in cancer patients.
Although genetic vaccines have the potential of being
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fit, there is still a need for optimization of vectors, injec-
tion schedules, and delivery methods. This will only be
achieved through carefully designed and conducted clin-
ical trials that include adequate methodology to measure
relevant immune responses.Abbreviations
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